Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Mokni, Walid ^a   Keravis, Thérèse ^a   Etienne Selloum, Nelly ^a   Walter, Alison ^a   Kane, Modou O ^a   Schini Kerth, Valérie B ^a   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; ISOENZYME; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 1A; PHOSPHODIESTERASE 1C; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG; CYBB PROTEIN, RAT; CYCLIC AMP; CYCLIC GMP; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; RAT; WISTAR RAT; ANIMAL; BIOLOGICAL MODEL; CARDIOMEGALY; CHEMISTRY; GENE EXPRESSION REGULATION; HEART VENTRICLE; HYDROLYSIS; METABOLISM; PATHOLOGY;

RATTUS;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART VENTRICLES; HYDROLYSIS; ISOENZYMES; MALE; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NADPH OXIDASE; RATS; RATS, WISTAR;

EID: 78649913343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014227     Document Type: Article

References (96)

1. Bayes-Genis A, Guindo J, Vinolas X, Tomas L, Elosua R, et al. (1995) Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Am J Cardiol 76: 54D-59D.
2. Weber KT, Brilla CG (1993) Structural basis for pathologic left ventricular hypertrophy. Clin Cardiol 16: II10-14.
3. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, et al. (2001) Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88: 961-968.
4. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. AmJ Physiol Cell Physiol 292: C82-97.
5. Touyz RM, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672.
6. Muller B, Lugnier C, Stoclet JC (1990) Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria. J Cardiovasc Pharmacol 15: 444-451.
7. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328.
8. Lugnier C, Stoclet JC (1979) Age related changes in cardiac and aortic phosphodiesterase activities in normotensive and hypertensive rats. Biochem Pharmacol 28: 3581-3587.
9. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748.
10. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
11. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65: 1-52.
12. Yanaka N, Kurosawa Y, Minami K, Kawai E, Omori K (2003) cGMPphosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles. Biosci Biotechnol Biochem 67: 973-979.
13. Takahashi K, Osanai T, Nakano T, Wakui M, Okumura K (2002) Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressureinduced congestive heart failure. Heart Vessels 16: 249-256.
14. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, et al. (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123: 25-35.
15. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, et al. (2009) Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice. Circulation.
16. Ding B, Abe J, Wei H, Huang Q, Walsh RA, et al. (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111: 2469-2476.
17. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, et al. (1997) Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96: 3116-3123.
18. Badenhorst D, Anamourlis C, Gibbs M, Maseko M, Osadchii O, et al. (2004) A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension. S Afr Med J 94: 833-834.
19. Wollert KC, Yurukova S, Kilic A, Begrow F, Fiedler B, et al. (2003) Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. Br J Pharmacol 140: 1227-1236.
20. Wegener JW, Nawrath H, Wolfsgruber W, Kuhbandner S, Werner C, et al. (2002) cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res 90: 18-20.
21. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238-248.
22. Takimoto E, Champion HC, Li M, Belardi D, Ren S, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222.
23. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, et al. (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294: H1398-1406.
24. Walter A, Etienne-Selloum N, Sarr M, Kane MO, Beretz A, et al. (2008) Angiotensin II Induces the Vascular Expression of VEGF and MMP-2 in vivo: Preventive Effect of Red Wine Polyphenols. J Vasc Res 45: 386-394.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
26. Kissane JM, Robins E (1958) The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J Biol Chem 233: 184-188.
27. Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C (2008) Shortterm or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol 154: 82-92.
28. Richter W, Jin SL, Conti M (2005) Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 388: 803-811.
29. Keravis T, Thaseldar-Roumie R, Lugnier C (2005) Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol 307: 63-74.
30. Lugnier C, Komas N (1993) Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 14 Suppl I: 141-148.
31. Podzuweit T, Nennstiel P, Muller A (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy- 3-nonyl) adenine. Cell Signal 7: 733-738.
32. Coste H, Grondin P (1995) Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol 50: 1577-1585.
33. Mery PF, Pavoine C, Pecker F, Fischmeister R (1996) EHNA as an Inhibitor of PDE2: A Pharmacological and Biochemical Study in Cardiac Myocytes. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase Inhibitors. London: Academic Press Limited. pp 81-88.
34. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
35. Yuan JS, Reed A, Chen F, Stewart CN, Jr. (2006) Statistical analysis of real-time PCR data. BMC Bioinformatics 7: 85.
36. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, et al. (2005) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96: 100-109.
37. Dyck JR, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574: 95-112.
38. Sirker A, Zhang M, Murdoch C, Shah AM (2007) Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol 27: 649-660.
39. Das DK, Maulik N, Engelman RM (2004) Redox regulation of angiotensin II signaling in the heart. J Cell Mol Med 8: 144-152.
40. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
41. Keravis T, Vandecasteele G, Mokni W, Fischmeister R, Lugnier C (2007) Identification of PDE1 et PDE5 in adult rat left ventricular cardiomyocytes. J Mol Cell Cardiol 42: S49-S50.
42. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, et al. (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99: 816-828.
43. Terrenoire C, Houslay MD, Baillie GS, Kass RS (2009) The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3. J Biol Chem 284: 9140-9146.
44. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G (2005) Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 142: 136-143.
45. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, et al. (2006) Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98: 226-234.
46. Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, et al. (2009) Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res 105: 784-792.
47. Baillie GS, Huston E, Scotland G, Hodgkin M, Gall I, et al. (2002) TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMPspecific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 277: 28298-28309.
48. Staton JM, Sayer MS, Hankey GJ, Attia J, Thakkinstian A, et al. (2006) Association between phosphodiesterase 4D gene and ischaemic stroke. J Neurol Neurosurg Psychiatry 77: 1067-1069.
49. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, et al. (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35: 131-138.
50. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, et al. (2001) Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276: 11189-11198.
51. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, et al. (2001) mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20: 1921-1930.
52. Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S, et al. (1999) Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472: 431-446.
53. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, et al. (2003) The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 278: 49230-49238.
54. Hashimoto Y, Sharma RK, Soderling TR (1989) Regulation of Ca2+/ calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 264: 10884-10887.
55. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, et al. (2009) Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105: 956-964.
56. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, et al. (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104: 2338-2343.
57. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, et al. (1997) Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 29: 3135-3146.
58. Vandeput F, Wolda SL, Krall J, Hambleton R, Uher L, et al. (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282: 32749-32757.
59. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90: 151-157.
60. Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, et al. (2007) Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol 292: L294-303.
61. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, et al. (2005) Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38: 175-184.
62. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, et al. (2008) Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal 20: 2231-2236.
63. Guazzi M, Arena R, Pinkstaff S, Guazzi MD (2008) Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol.
64. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119: 408-420.
65. Lewis GD, Semigran MJ (2006) The emerging role for type 5 phosphodiesterase inhibition in heart failure. Curr Heart Fail Rep 3: 123-128.
66. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, et al. (2003) Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 23: 6452-6459.
67. Francis SH, Corbin JD, Bischoff E (2009) Cyclic GMP-hydrolyzing phosphodiesterases. Handb Exp Pharmacol. pp 367-408.
68. Ang KL, Antoni FA (2002) Reciprocal regulation of calcium dependent and calcium independent cyclic AMP hydrolysis by protein phosphorylation. J Neurochem 81: 422-433.
69. Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, et al. (2006) Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem Biophys Res Commun 341: 837-846.
70. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
71. Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, et al. (2006) Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98: 777-784.
72. Stehlik J, Movsesian MA (2009) Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail 15: 31-34.
73. Evgenov OV, Busch CJ, Evgenov NV, Liu R, Petersen B, et al. (2006) Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290: L723-L729.
74. Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, et al. (2005) Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res 6: 76.
75. Geoffroy V, Fouque F, Nivet V, Clot JP, Lugnier C, et al. (1999) Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgiendosomal fraction. Eur J Biochem 259: 892-900.
76. Castro LR, Verde I, Cooper DM, Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113: 2221-2228.
77. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, et al. (1995) Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96: 1059-1065.
78. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, et al. (2007) Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49: 1079-1088.
79. Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMPactivated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58: 1953-1960.
80. Hutchinson DS, Summers RJ, Bengtsson T (2008) Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther 119: 291-310.
81. Arad M, Seidman CE, Seidman JG (2007) AMP-activated protein kinase in the heart: role during health and disease. Circ Res 100: 474-488.
82. Du J, Guan T, Zhang H, Xia Y, Liu F, et al. (2008) Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 368: 402-407.
83. Wang Y, Gao E, Tao L, Lau WB, Yuan Y, et al. (2009) AMP-Activated Protein Kinase Deficiency Enhances Myocardial Ischemia/Reperfusion Injury but Has Minimal Effect on the Antioxidant/Antinitrative Protection of Adiponectin. Circulation.
84. Zhang P, Hu X, Xu X, Fassett J, Zhu G, et al. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52: 918-924.
85. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Yong Ji S, et al. (2009) Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure. Circ Res 104: 403-411.
86. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, et al. (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283: 24194-24201.
87. Stuck BJ, Lenski M, Bohm M, Laufs U (2008) Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 283: 32562-32569.
88. Li HL, Yin R, Chen D, Liu D, Wang D, et al. (2007) Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload- induced cardiac hypertrophy. J Cell Biochem 100: 1086-1099.
89. Lamberts RR, Onderwater G, Hamdani N, Vreden MJ, Steenhuisen J, et al. (2009) Reactive oxygen species-induced stimulation of 59AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation 120: S10-15.
90. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM (2009) NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 47: 15-22.
91. Anilkumar N, Sirker A, Shah AM (2009) Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci 14: 3168-3187.
92. Hingtgen SD, Tian X, Yang J, Dunlay SM, Peek AS, et al. (2006) Nox2- containing NADPH oxidase and Akt activation play a key role in angiotensin IIinduced cardiomyocyte hypertrophy. Physiol Genomics 26: 180-191.
93. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, et al. (2006) Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72: 112-123.
94. Wang S, Zhang M, Liang B, Xu J, Xie Z, et al. (2010) AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 106: 1117-1128.
95. Schulz E, Dopheide J, Schuhmacher S, Thomas SR, Chen K, et al. (2008) Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation 118: 1347-1357.
96. Schulz E, Schuhmacher S, Munzel T (2009) When metabolism rules perfusion: AMPK-mediated endothelial nitric oxide synthase activation. Circ Res 104: 422-424.